How Much Upside is Left in Oddity Tech (ODD)? Wall Street Analysts Think 57.63%

The consensus price target hints at a 57.6% upside potential for Oddity Tech (ODD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Dec 3, 2025

Oddity Tech (ODD) Upgraded to Buy: What Does It Mean for the Stock?

Oddity Tech (ODD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Dec 3, 2025

Oddity Tech: When Beauty Becomes A Data Business

Oddity combines high growth, profitability, and a data-driven advantage, differentiating it from traditional beauty brands and creating a compelling investment case. ODD leverages machine learning and direct-to-consumer models, fueling rapid revenue growth, high margins, and successful brand launches like IL MAKIAGE, SpoiledChild, and METHODIQ. After a 50% pullback, ODD trades at an attractive valuation. If growth continues, the risk-reward profile is favorable, and the stock is considered a 'Buy'.

Seeking Alpha • Nov 26, 2025

Why Oddity Tech Stock Rallied Today

Oddity's sales and profits are growing at an impressive clip. Management sees further gain ahead.

The Motley Fool • Nov 20, 2025

Oddity Tech Ltd. (ODD) Q3 2025 Earnings Call Transcript

Oddity Tech Ltd. ( ODD ) Q3 2025 Earnings Call November 20, 2025 8:30 AM EST Company Participants Maria Lycouris Oran Holtzman - Co-Founder, CEO & Director Lindsay Mann - Global Chief Financial Officer Conference Call Participants Dara Mohsenian - Morgan Stanley, Research Division Anna Lizzul - BofA Securities, Research Division Youssef Squali - Truist Securities, Inc., Research Division Andrew Boone - Citizens JMP Securities, LLC, Research Division Cory Carpenter - JPMorgan Chase & Co, Research Division Ryan MacDonald - Needham & Company, LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Bonnie Herzog - Goldman Sachs Group, Inc., Research Division Georgia Anderson - Evercore ISI Institutional Equities, Research Division Lauren Lieberman - Barclays Bank PLC, Research Division Brian Tanquilut - Jefferies LLC, Research Division Presentation Operator Good morning.

Seeking Alpha • Nov 20, 2025

ODDITY Tech Reports Record Third Quarter Results, Raises Full Year Outlook

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced its financial results for the third quarter ended September 30, 2025.

GlobeNewsWire • Nov 19, 2025

Oddity Tech (ODD) Q3 Earnings and Revenues Top Estimates

Oddity Tech (ODD) came out with quarterly earnings of $0.4 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.32 per share a year ago.

Zacks Investment Research • Nov 19, 2025

ODDITY Launches METHODIQ, a Telehealth Platform Reimagining Medical Care

NEW YORK--(BUSINESS WIRE)--ODDITY Tech Ltd. (NASDAQ: ODD) today announced the launch of METHODIQ, a medical telehealth platform delivering customized, high-efficacy treatments powered by online diagnosis – without needing to go to a doctor's office or get lost in a drug store. METHODIQ reimagines medical care with science, world-class treatments and AI analysis to deliver the highest standards of care – accessible to everyone. The platform begins with dermatology treatments for acne, hyperpigme.

Business Wire • Nov 18, 2025

Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq

Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and cosmetics, that address acne, hyperpigmentation and eczema and range in price from about $29 to around $59.

CNBC • Nov 18, 2025

Top 3 Defensive Stocks That Could Lead To Your Biggest Gains In Q4

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Benzinga • Nov 13, 2025